PharmGen Science, Inc. (KRX:004720)
South Korea
· Delayed Price · Currency is KRW 3,950.00
-5.00 (-0.13%)
At close: Apr 16, 2025, 3:30 PM KST
PharmGen Science Revenue
In the year 2024, PharmGen Science had annual revenue of 171.29B KRW with 2.70% growth. PharmGen Science had revenue of 44.23B in the quarter ending December 31, 2024, a decrease of -4.97%.
Revenue
171.29B
Revenue Growth
+2.70%
P/S Ratio
0.43
Revenue / Employee
674.36M
Employees
254
Market Cap
73.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 171.29B | 4.51B | 2.70% |
| Dec 31, 2023 | 166.78B | 15.85B | 10.50% |
| Dec 31, 2022 | 150.93B | 41.06B | 37.38% |
| Dec 31, 2021 | 109.87B | 13.25B | 13.72% |
| Dec 31, 2020 | 96.61B | 1.48B | 1.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| Peptron | 3.15B |
| LigaChem Biosciences | 125.90B |